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Abstract
Objectives This study aims to pilot a community pharmacy chronic obstructive
pulmonary disease (COPD) case finding service in England, estimating costs and
effects.
Methods Patients potentially at risk of COPD were screened with validated tools.
Smoking cessation was offered to all smokers identified as potentially having undi-
agnosed COPD.Cost and effects of the service were estimated.
Key findings Twenty-one community pharmacies screened 238 patients over 9
months. One hundred thirty-five patients were identified with potentially undiag-
nosedCOPD; 88were smokers. Smoking cessation initiation provided a project gain
of 38.62 life years, 19.92 quality-adjusted life years and a cost saving of £392.67 per
patient screened.
Conclusions COPD case finding by community pharmacists potentially provides
cost-savings and improves quality of life.
Introduction
With just under 1million cases of chronic obstructive pulmo-
nary disease (COPD) in England, the direct cost to theNHS is
estimated to be £900M.[1] Treating late stageCOPD is believed
to cost 10 times more than moderate disease,[2] and conse-
quently interventions that prevent progression are likely to
realise significant healthcare savings.
COPD is a progressive degenerative disease that can be
checked if the underlying cause, e.g. smoking is removed. It is
estimated that there are 2.8 million undetected cases of
COPD in the UK and if these remain undiagnosed or are
diagnosed late, this is predicted to cost the NHS £3.22
Billion.[3]
One approach to early detection is case-finding which
consists of screening people at risk of COPD using a
symptom questionnaire[4] and spirometry test to evaluate
lung function.[5] Although such an approach by general
practitioners in the UK has been demonstrated to be effec-
tive[6] and a similar model has been piloted in community
pharmacy in Spain,[7] it has not been tested in community
pharmacy in the UK.
The aim of this service evaluation was to deliver a COPD
case finding service in a range of community pharmacies in
England and estimate the cost and effects associated with its
delivery.
Methods
Approval for the service evaluation was obtained from the
University ethical committee. Twenty-one community phar-
macies within theWirral area, representing four large multi-
ple companies, delivered the case finding service from
September 2012 until April 2013. Figure 1 summarises
recruitment and assessment processes used within the study.
The validated disease risk assessment questionnaire[4] used
ascertained the following:
• age over 35;
• whether smoked at least 100 cigarettes in entire life;
• number of times short of breath in previous four weeks;
• whether they ever cough upmucus or phlegm; and
• whether breathing problems affect usual activities.
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With each response graded out of 2, a score of greater than
5 (84.4% sensitivity, 60.7% specificity for diagnosis of mod-
erately severe COPD) resulted in general practitioner (GP)
referral.
Micro-spirometry (use of hand-held spirometers) was
used to determine amount of air forcibly exhaled (forced
expiratory volume) at 1 and 6 seconds (FEV1 and FEV6). An
FEV1 to FEV6 ratio of less than 0.7 (diagnosis criteria for
COPD[5]) or FEV1 less than 80% of what would be predicted
to be normal (indicative of moderately severe COPD[5]), also
resulted in GP referral. Patients were given lifestyle advice,
signposted to or offered smoking cessation support (nature
of which was dependant on local arrangements) and/or
referred to their GP.
Number of assessments, patient demographics and the
results from the assessments were recorded.
The projected costs and effects associated with the service
were estimated utilising the following assumptions:
• Patients identifiedwithCOPDwere atGOLDstage 2 (mod-
erate severity).[5]
• Life time cost savings from stopping smoking amounted to
£1062 per patient while gains of 0.45 life years and 0.23
quality-adjusted life years (QALYs) would be realised
assuming 33% smoking cessation success rate in those who
were identified.[8]
Results
Two hundred thirty-eight patients identified as either
smokers or regular purchasers of coughmedicines consented
to be screened, 141 (59.2%) were women and the mean age
was 51.2 years.
One hundted twenty four (52.1%) of those screened were
current smokers of which 84 (67.7%) expressed an interest in
smoking cessation.
One hundted thirty-five (56.7%) of those screened were
identified at risk of COPD (71 questionnaire, 85 FEV
ratio < 80% and 39 FEV < 0.7) and 88 (65.2%) of which were
current smokers. 34 (38.6%) of the current smokers refused
smoking cessation service, 16 (18.2%) received a smoking
cessation service from the pharmacist in-house, whereas 30
(34.1%) were referred to an external service. For eight (9.1%)
patients data were not available. An additional nine patients,
not identified at risk of COPD, undertook smoking cessation
service in-house and 14 were referred.
General lifestyle advice was given to 150 patients of which
98 (65.3%) was related to smoking, 32 (21.3%) diet and
nutrition, 51 (34.0%) physical activity, 17 (11.3%) alcohol, 11
(7.3%) weight management and 19 (12.7%) other.
Based on assumptions stated in the method, in the 88
patients at risk of COPDwho were smokers, possible net cost
savings of £93 456 were estimated within the project with a
total lifetime gain of 38.62 life years and 19.92 QALYs. The
cost saving per patient screened is therefore £392.67.
If the proportion identified at risk in the pilot study held
nationally thenwith a per pharmacy capture rate of 50within
11 100 pharmacies, then this would yield 205 175 patients at
risk and actively smoking realising £214.7 million in savings,
90 052 life years and 46 448 QALYs.
Discussion and Conclusion
This evaluation shows that community pharmacists can
effectively undertake case finding of COPD and that a
method of targeted screening identifies one patient with
moderate severity COPD for every two screened. This ratio
may vary depending on geographical location and such ser-
vices may be more cost-effective in areas of known high
COPD prevalence.
Although the number of type of pharmacies improves the
generalisability of the results, this is service evaluation and
consequently the effect of not providing the service is
unknown. Additionally, estimates of costs and effects are
derived from theoretical economicmodels based on assump-
tions that may not accurately reflect reality.
The simple cost analysis that is based on the smoking ces-
sation element alone however suggests that providing the cost
per patient screened is less than £400 than the service should
be adopted by theNHS.With the transition frommoderate to
severeCOPDestimated to cost theNHS£1000 per patient per
year[3] and the productivity losses from COPD estimated at
£819.66 per patient per year[9] early identification from the
cases-finding service will realise additional savings to both
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Figure 1 Summary of recruitment and assessment process.
2 Community pharmacy COPD case finding service
© 2014 The Authors. International Journal of Pharmacy Practice published by
John Wiley & Sons Ltd on behalf of Royal Pharmaceutical Society
International Journal of Pharmacy Practice 2014, ••, pp. ••–••
the NHS and society. The service additionally identified-
smokers without COPD who were willing to consider and
access smoking cessation services.
The results from this service evaluation strongly suggest
that if the results were replicated nationally, a pharmacist
delivered COPD case finding service could potentially
provide significant NHS and societal benefits is likely to be
cost-effective and therefore should be adopted.
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